Cantor Fitzgerald reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report released on Wednesday morning. The brokerage currently has a $9.00 price objective on the biopharmaceutical company’s stock.
“Glemba Top-line Data in 2Q18. The METRIC trial enrolled a total of 327 patients, 203 of which need to reach progression events for evaluation of the primary endpoint. Although the expectations for the data have been modest, we are optimistic based on EMERGE’s (Phase II) PFS of 3.5 months and the achievement of OS in a cross-over design study. The trial uses a cutoff of 25% gpNMB expression and is powered at 85%, for a hazard ratio of less than or equal to 0.64. If successful, the program will serve as a basis for the BLA filing in 2H19, and we would expect CLDX to pursue a partnership.”,” the firm’s analyst wrote.
A number of other equities analysts also recently weighed in on the stock. BidaskClub raised shares of Celldex Therapeutics from a strong sell rating to a sell rating in a research note on Friday, January 5th. HC Wainwright reaffirmed a buy rating on shares of Celldex Therapeutics in a research note on Tuesday, November 7th. Finally, WBB Securities reaffirmed a buy rating and set a $10.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.08. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative net margin of 730.06% and a negative return on equity of 44.64%. Celldex Therapeutics’s revenue was up 87.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.30) earnings per share. analysts anticipate that Celldex Therapeutics will post -0.9 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of CLDX. Teachers Advisors LLC raised its stake in Celldex Therapeutics by 64.9% during the second quarter. Teachers Advisors LLC now owns 288,073 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 113,368 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Celldex Therapeutics by 22.6% in the second quarter. TIAA CREF Investment Management LLC now owns 314,485 shares of the biopharmaceutical company’s stock worth $777,000 after acquiring an additional 57,909 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Celldex Therapeutics in the second quarter worth $943,000. Nationwide Fund Advisors increased its position in shares of Celldex Therapeutics by 3.5% in the second quarter. Nationwide Fund Advisors now owns 111,757 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 3,742 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Celldex Therapeutics by 12.2% in the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 219,661 shares in the last quarter. 57.55% of the stock is currently owned by institutional investors.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.